Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983828 | 0.83 | KMT2A (0.61) | RAB9ANPC1MEN1POLBKMT2A | |
| SCHEMBL3592465 | 0.83 | RAB9A (1.00) | RAB9ANPC1MEN1POLBKMT2A | |
| SCHEMBL3592470 | 0.83 | RAB9A (1.00) | RAB9ANPC1MEN1POLBKMT2A | |
| SCHEMBL28758521 | 0.82 | RAB9A (0.50) | RAB9ANPC1MEN1POLBKMT2A | |
| SCHEMBL2303662 | 0.81 | KMT2A (0.59) | RAB9ANPC1MEN1POLBKMT2A | |
| Styrene SCHEMBL4406221 | 0.80 | RAB9A (0.63) | RAB9ANPC1MEN1POLBKMT2A | |
| SCHEMBL7827702 | 0.79 | SIGMAR1 (0.56) | RAB9ANPC1MEN1POLBKMT2A | |
| SCHEMBL28649066 | 0.77 | RAB9A (0.59) | RAB9ANPC1MEN1KMT2ALMNA | |
| SCHEMBL23244219 | 0.76 | ME2 (0.74) | NPC1MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL4052147 | 0.75 | RAB9A (0.56) | RAB9ANPC1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | claimed |
| EP-1744755-A4 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2009-07-15 | — | — | EP | claimed |
| JP-2007535568-A | — | — | 2007-12-06 | — | — | JP | claimed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | claimed |
| EP-1744755-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | claimed |
| WO-2005107464-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2005-11-17 | — | — | WO | claimed |
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| EP-1744755-A4 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2009-07-15 | — | — | EP | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| EP-1744755-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| WO-2005107464-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSF | RAB9A 480/4885NPC1 47/4885MEN1 3478/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | RAB9A 2095/4885NPC1 32/4885MEN1 1637/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | RAB9A 2095/4885NPC1 32/4885MEN1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.